Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    es104
Previous Study | Return to List | Next Study

A Study of ES104 in Patients With Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05167448
Recruitment Status : Recruiting
First Posted : December 22, 2021
Last Update Posted : March 23, 2022
Sponsor:
Information provided by (Responsible Party):
Elpiscience (Suzhou) Biopharma, Ltd.

Brief Summary:
The purpose of this open-label, Multicenter Phase I/II study is to evaluate the safety, tolerability, preliminary anti-tumor efficay, pharmacokinetics, anti-drug antibodies and biomarkers of ES104 in patients with unresectable locally advanced or metastatic colorectal cancer who have failed systemic therapies.

Condition or disease Intervention/treatment Phase
Metastatic Colorectal Cancer Drug: ES104 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 58 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Clinical Trial of ES104 in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer Who Have Failed Systemic Therapies
Actual Study Start Date : February 25, 2022
Estimated Primary Completion Date : May 31, 2026
Estimated Study Completion Date : July 31, 2026

Arm Intervention/treatment
Experimental: Cohort 1 Phase 1 Drug: ES104
ES104 is administered via Intravenous infusion, at dose of 10 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.

Experimental: Cohort 2 Phase 1 Drug: ES104
ES104 is administered via Intravenous infusion, at dose of 12.5 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.

Experimental: RP2D Phase 2 Drug: ES104
ES104 is administered via Intravenous infusion, at dose of RP2D, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.




Primary Outcome Measures :
  1. Phase 1: The frequency and severity of adverse events of ES104 [ Time Frame: 1-3 years ]
    The safety profile of ES104 will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

  2. Phase 2: The anti-tumor activity of ES104 [ Time Frame: 2-5 years ]
    The Objective Remission Rate (ORR) will be measured by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1) by Investigator assessment.


Secondary Outcome Measures :
  1. Phase 1: Maximum observed serum concentration (Cmax) of ES104 [ Time Frame: 1-3 years ]
    Maximum observed serum concentration (Cmax) of ES104 will be measured.

  2. Phase 1:Time to Cmax (Tmax) of ES104 [ Time Frame: 1-3 years ]
    Time to Cmax (Tmax) of ES104 will be measured.

  3. Phase 1:Area under the serum concentration time curve (AUC) of ES104 [ Time Frame: 1-3 years ]
    Area under the serum concentration time curve (AUC) of ES104 will be measured.

  4. Phase 1:The clearance of ES104 [ Time Frame: 1-3 years ]
    A pharmacokinetic measurement of the volume of plasma from which ES104 is completely removed per unit time.

  5. Phase 1: The immunogenicity of ES104 [ Time Frame: 1-3 years ]
    The presence and the frequency of anti-drug antibodies (ADA) against ES104 will be measured.

  6. Phase 1: The preliminary anti-tumor activity of ES104 [ Time Frame: 1-3 years ]
    Tumor response will be measured by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1) by Investigator assessment.

  7. Phase 2: The anti-tumor activity of ES104 [ Time Frame: 2-5 years ]
    Tumor response will be measured by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1) by Investigator assessment.

  8. Phase 2: The frequency and severity of adverse events of ES104 [ Time Frame: 2-5 years ]
    The safety profile of ES104 will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.

  9. Phase 2: The popPK profile of ES104 [ Time Frame: 2-5 years ]
    The Cmin,ss、CL and Vd of ES104 will be measured.

  10. Phase 2: The immunogenicity of ES104 [ Time Frame: 2-5 years ]
    The presence and the frequency of anti-drug antibodies (ADA) against ES104 will be measured.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability to understand and the willingness to sign a written informed consent form.
  • Locally advanced or metastatic colorectal adenocarcinoma confirmed by pathology and not surgically resectable, having received systemic therapy and failed.
  • At least one measurable lesion is required (RECIST v1.1)
  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
  • Estimated life expectancy, in the judgment of the investigator, of at least 12 weeks.
  • Adequate organ function, as assessed by the results of the laboratory tests specified in the protocol.
  • Male and female subjects of childbearing potential must be willing to use effective contraceptive methods, from the time of signing informed consent and for the duration of study participation through 180 days following the last dose of study drug.

Exclusion Criteria:

  • Receipt of any systemic antitumor therapy within 28 days prior to the first dose of study drug.
  • Known history of severe allergy to any monoclonal antibody or study drug excipient.
  • The subject has received or is receiving treatment in another clinical trial within 28 days prior to the first dose of study drug (except for participation in the overall survival follow-up of a study)
  • Receipt of antiplatelet agents or anticoagulants for therapeutic purposes within 14 days prior to the first dose of study drug.
  • Receipt of live vaccination within 28 days prior to the first dose of study drug.
  • Prior history of allogeneic organ transplantation or allogeneic peripheral blood stem cell (PBSC)/bone marrow transplantation treatment.
  • Subject has not recovered from all AEs of previous anticancer therapies to baseline or ≤ Grade 1 per CTCAE v5.0 before the first dose of study drug. Certain exceptions as defined in protocol apply.
  • Subjects with active metastatic brain or meningeal metastases.
  • Patients with other primary malignancies within 5 years before the first dose of study drug. Some exceptions as defined per protocol apply.
  • Major surgery or major traumatic injury within 28 days prior to the first dose of study drug (in the judgment of the Investigator).
  • History of cardiovascular disease as defined by the protocol within the past 5 years.
  • History of bleeding-related illness as defined by the protocol.
  • Presence of severe, unhealed or open wounds and active ulcers or untreated fractures.
  • Known history of human immunodeficiency virus (HIV) virus infection and/or acquired immunodeficiency syndrome.
  • Chronic active hepatitis B or active hepatitis C.
  • Active infection requiring systemic therapy 14 days prior to first dose of study drug.
  • Pregnant or nursing females.
  • Known history of alcohol or drug abuse.
  • Subjects with comorbidities or other conditions that may affect compliance with the protocol or are not suitable for participation in this study in the judgment of the Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05167448


Contacts
Layout table for location contacts
Contact: Chang Su +86 021-50651310 clinical-operation@elpiscience.com

Locations
Layout table for location information
China
Beijing Cancer Hospital Recruiting
Beijing, China
Contact: Lin Shen, Doctor         
Sponsors and Collaborators
Elpiscience (Suzhou) Biopharma, Ltd.
Layout table for additonal information
Responsible Party: Elpiscience (Suzhou) Biopharma, Ltd.
ClinicalTrials.gov Identifier: NCT05167448    
Other Study ID Numbers: ES104-1001
First Posted: December 22, 2021    Key Record Dates
Last Update Posted: March 23, 2022
Last Verified: December 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Elpiscience (Suzhou) Biopharma, Ltd.:
ES104
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases